Chronic Low Back Pain Clinical Trial
Official title:
The Identification of Prognostic Indicators for Exercise Therapy in Patients With Nonspecific Chronic Low Back Pain: A Multicenter Trial
There is a consensus that exercise therapy should be used as a therapy approach in CLBP but
little consensus has been reached about the preferential type of therapy. There occurs to be
a wash out effect because of the heterogeneous character of CLBP patients. As a result, no
effect can be demonstrated for the entire sample. This is why one should consider creating
subgroups based on prognostic indicators.
Objectives for this trial is to possibly identify prognostic indicators for treatment
response to three forms of exercise therapy for patients with nonspecific chronic low back
pain (CLBP).
The study design is a multicenter cohort design. Patients with nonspecific low back pain of
more than three months duration are recruited in two different hospitals (Antwerp University
Hospital and Sint Vincentius Hospital). After examination patients are assigned to one of
three intervention groups: motor control therapy, isometric training therapy and a
combination therapy. All patients will undergo eighteen treatment sessions during nine weeks.
Measurements will be taken at baseline and after nine weeks of treatment.
The primary outcome used is the Modified Oswestry Disability Questionnaire (MDQ). For each
type of exercise therapy prognostic indicators will be investigated.
Never before a multi-arm design was performed for the identification of prognostic indicators
for exercise therapy in patients with nonspecific CLBP.
Methods/ Design
Ethical approval (B300201215600) was obtained from the local ethics committees of the Antwerp
University Hospital.
Study design In the identification of prognostic indicators is derived from a number of
variables that have predictive potential for therapy outcome. These variables are obtained
from baseline measurements and have a multidimensional character (impairments,
activities/participation and contextual factors).
Patient recruitment Patients will be recruited by doctors at the service of two settings
located in Antwerp namely the Antwerp University Hospital (UZA) and the Sint-Vincentius
Hospital. Treatment and measurements will be performed at the site where the patient has been
recruited.
Inclusion criteria: Current nonspecific LBP persisting at least three months, consulted a
medical doctor during the last month because of the persistent low back pain, age between 18
and 60, sufficient fluency in Dutch to follow treatment instructions and answer survey
questions.
Exclusion criteria: spinal canal stenosis, spondylolisthesis and spondylitis, large herniated
disc sciatica, radiating pain below the knee, previous back surgery, a history of known
spinal fractures, malignancy, known muscle-, nerve-, skin-, or joint diseases, pregnancy and
lack of consent.
Measurements
Baseline testing As primary (dependent) outcome measure the Modified Oswestry Disability
Questionnaire is used (MDQ). The MDQ is a disease specific questionnaire to measure
disability in LBP patients [21-23].
As secondary (independent) outcome measures the following tests are used:
First, Measurement of impairments: duration of the LBP/ pelvis impairments / respiratory
impairments (all three items through anamnesis). Prone instability test, Straight Leg Raise,
Beighton scale, Active Straight Leg Raise, sitting knee extension test, waiters bow, pelvic
tilt, side support test, extensor endurance test, active sit-up, Visual Analogue Scale for
pain (VAS).
Second, measurement of limitations in activities and participation: hours of physical
activity/week (trough anamnesis). Short Form 36 Health Survey (SF36), Roland Morris
Disability Questionnaire (RMDQ).
Third, measurement of contextual factors: gender/ age / height / weight / body mass index /
smoking / profession / underwent previous therapy / comorbidity (trough anamnesis). Tampa
scale for kinesiophobia, Fear Avoidance Belief Questionnaire (FABQ), We performed a
literature search to select all used clinical tests based on their reliability and validity
[24]. The Baseline testing takes about 30 minutes.
Follow-up
Follow up takes place after completion of the treatment program at nine weeks. All patient
reported outcome measures (PROMs) from the baseline testing will be re-evaluated at this
moment.
Randomization & blinding
In the Sint-Vincentius Hospital, all included patients will follow the combination treatment
since this is the only intervention group which is being organized in this hospital.
In the UZA, patients will be randomly assigned into one of the two treatment groups (motor
control or isometric training) after baseline testing. The responsible researcher will use a
randomization list generated with Microsoft ® Excel ® software (version 14.3.9, 2010 ©
Microsoft Corporation).
Intervention
During the nine weeks intervention, patients will be treated two times a week. Patients will
be assigned randomly into one of three intervention groups (motor control therapy, isometric
training therapy or combination therapy). Each intervention will take about seventy minutes.
Ten minutes warming up and cooling down will be the same in each treatment regime. Each group
receives fifty minutes of therapy specific intervention. Previously trained physiotherapists
will give the treatment. To ensure that all therapists provide the same exercises, a
treatment protocol for each treatment group was developed and a treatment diary will be
filled out after each session.
Interventions in derivation and validation phase are similar.
Power analysis
This study describes the identification of prognostic indicators in which the therapeutic
effect of the interventions cannot be predicted. Therefore, a two-tailed hypothesis was used
to calculate the power. A pilot study showed that the standard deviation of the primary
outcome measure, MDQ, is set at 10.53.6 Given these estimates, 54 patients were needed to
detect a minimum clinically important difference (MCID, effect size 0.84) with 90% power.
Consequently, three groups of 18 patients were needed to complete the trial.
Data analysis
Prognostic indicators aim to detect potential predictive variables for treatment success
(dichotomous, yes/no) in a set of baseline measurements. A minimal decrease in the MDQ score
of 9 points is considered as treatment success.
Potential predictive variables are selected as follows: first, individual variables from the
self-reports, history, and physical examination are tested for their bivariate association
with the reference standard using independent sample t tests, Mann-Whitney U tests or
Chi-square tests based on the nature of the data. Variables with a significance level of P <
0.10 are retained as potential prediction variables. We choose a more liberal significance
level at this stage to avoid excluding potential predictive variables.
This statistical analysis is performed for each treatment group (motor control therapy,
general active exercise therapy and isometric training therapy).
Information form and informed consent
If patients meet the in- and exclusion criteria they are scheduled for an interview with one
of our researchers to be informed about the trial. If patients decide to participate they
will sign an informed consent. Information form and informed consent are made and have been
approved by the ethics committee of the University of Antwerp.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00613106 -
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
|
Phase 3 |